View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 3, 2011

Lucentis Injection Shows Efficacy for Diabetic Macular Oedema

Genentech has announced the successful clinical results from the two Phase III trials of Lucentis (ranibizumab injection) in people with diabetic macular oedema. The 36-month multicentre, randomised, double-masked and sham injection-controlled RISE and RIDE studies evaluated the effica

By cms admin

Genentech has announced the successful clinical results from the two Phase III trials of Lucentis (ranibizumab injection) in people with diabetic macular oedema.

The 36-month multicentre, randomised, double-masked and sham injection-controlled RISE and RIDE studies evaluated the efficacy and safety of Lucentis in patients with this condition.

The studies also demonstrated that Lucentis showed rapid and sustained improvement in vision compared to placebo injections.

The drug-related side effects include infections inside the eye, detached retinas, cataracts, nose and throat infections, headache and respiratory infections.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology